|
1
|
Udan RS, Kangosingh M, Nolo R, Tao C and
Halder G: Hippo promotes proliferation arrest and apoptosis in the
Salvador/Warts pathway. Nat Cell Biol. 5:914–920. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Varelas X: The Hippo pathway effectors TAZ
and YAP in development, homeostasis and disease. Development.
141:1614–1626. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Halder G and Johnson RL: Hippo signaling:
Growth control and beyond. Development. 138:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pan D: The hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu FX and Guan KL: The Hippo pathway:
Regulators and regulations. Genes Dev. 27:355–371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu FX, Zhao B and Guan KL: Hippo pathway
in organ size control, tissue homeostasis, and cancer. Cell.
163:811–828. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wierzbicki PM and Rybarczyk A: The Hippo
pathway in colorectal cancer. Folia Histochem Cytobiol. 53:105–119.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shi P, Feng J and Chen C: Hippo pathway in
mammary gland development and breast cancer. Acta Biochim Biophys
Sin (Shanghai). 47:53–59. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Y, Ding W, Chen C, Niu Z, Pan M and
Zhang H: Roles of Hippo signaling in lung cancer. Indian J Cancer.
52 Suppl 1:e1–e5. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen M, Wang M, Xu S, Guo X and Jiang J:
Upregulation of miR-181c contributes to chemoresistance in
pancreatic cancer by inactivating the Hippo signaling pathway.
Oncotarget. 6:44466–44479. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mo JS, Park HW and Guan KL: The Hippo
signaling pathway in stem cell biology and cancer. EMBO Rep.
15:642–656. 2014.PubMed/NCBI
|
|
13
|
Herrmann J, Lerman LO and Lerman A:
Ubiquitin and ubiquitin-like proteins in protein regulation. Circ
Res. 100:1276–1291. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hanpude P, Bhattacharya S, Dey AK and
Maiti TK: Deubiquitinating enzymes in cellular signaling and
disease regulation. IUBMB Life. 67:544–555. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wilkinson KD: Ubiquitination and
deubiquitination: Targeting of proteins for degradation by the
proteasome. Semin Cell Dev Biol. 11:141–148. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hong W and Guan KL: The YAP and TAZ
transcription co-activators: Key downstream effectors of the
mammalian Hippo pathway. Semin Cell Dev Biol. 23:785–793. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hansen CG, Moroishi T and Guan KL: YAP and
TAZ: A nexus for Hippo signaling and beyond. Trends Cell Biol.
25:499–513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu
J, Lin JD, Wang CY, Chinnaiyan AM, et al: TEAD mediates
YAP-dependent gene induction and growth control. Genes Dev.
22:1962–1971. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Strano S, Monti O, Baccarini A, Sudol M,
Sacchi A, Oren M, Sudol M, Cesareni G and Blandino G: Physical
interaction with yes-associated protein enhances p73
transcriptional activity. J Biol Chem. 37:15164–15173. 2001.
View Article : Google Scholar
|
|
20
|
Alarcón C, Zaromytidou AI, Xi Q, Gao S, Yu
J, Fujisawa S, Barlas A, Miller AN, Manova-Todorova K, Macias MJ,
et al: Nuclear CDKs drive Smad transcriptional activation and
turnover in BMP and TGF-beta pathways. Cell. 139:757–769. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Varelas X, Sakuma R, Samavarchitehrani P,
Peerani R, Rao BM, Dembowy J, Yaffe MB, Zandstra PW and Wrana JL:
TAZ controls Smad nucleocytoplasmic shuttling and regulates human
embryonic stem-cell self-renewal. Nat Cell Biol. 10:837–848. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ferrigno O, Lallemand F, Verrecchia F,
L'Hoste S, Camonis J, Atfi A and Mauviel A: Yes-associated protein
(YAP65) interacts with Smad7 and potentiates its inhibitory
activity against TGF-beta/Smad signaling. Oncogene. 21:4879–4884.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kelleher FC and O'Sullivan H: FOXM1 in
sarcoma: Role in cell cycle, pluripotency genes and stem cell
pathways. Oncotarget. 7:42792–42804. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Murakami M, Nakagawa M, Olson EN and
Nakagawa O: A WW domain protein TAZ is a critical coactivator for
TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc
Natl Acad Sci USA. 102:18034–18039. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rosenbluh J, Nijhawan D, Cox AG, Li X,
Neal JT, Schafer EJ, Zack TI, Wang X, Tsherniak A, Schinzel AC, et
al: β-Catenin-driven cancers require a YAP1 transcriptional complex
for survival and tumorigenesis. Cell. 151:1457–1473. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yagi R, Chen LF, Shigesada K, Murakami Y
and Ito Y: A WW domain-containing Yes-associated protein (YAP) is a
novel transcriptional co-activator. EMBO J. 18:2551–2562. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang W, Gao Y, Li P, Shi Z, Guo T, Li F,
Han X, Feng Y, Zheng C, Wang Z, et al: VGLL4 functions as a new
tumor suppressor in lung cancer by negatively regulating the
YAP-TEAD transcriptional complex. Cell Res. 24:331–343. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao B, Lei QY and Guan KL: The Hippo-YAP
pathway: New connections between regulation of organ size and
cancer. Curr Opin Cell Biol. 20:638–646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ahn EY, Kim JS, Kim GJ and Park YN:
RASSF1A-mediated regulation of AREG via the Hippo pathway in
hepatocellular carcinoma. Mol Cancer Res. 11:748–758. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ma K, Xu Q, Wang S, Zhang W, Liu M, Liang
S, Zhu H and Xu N: Nuclear accumulation of Yes-Associated Protein
(YAP) maintains the survival of doxorubicin-induced senescent cells
by promoting survivin expression. Cancer Lett. 375:84–91. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Staley BK and Irvine KD: Hippo signaling
in Drosophila: Recent advances and insights. Dev Dyn.
241:3–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Boggiano JC, Vanderzalm PJ and Fehon RG:
Tao-1 phosphorylates Hippo/MST kinases to regulate the
Hippo-Salvador-Warts tumor suppressor pathway. Dev Cell.
21:888–895. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang HL, Wang S, Yin MX, Dong L, Wang C,
Wu W, Lu Y, Feng M, Dai C, Guo X, et al: Par-1 regulates tissue
growth by influencing Hippo phosphorylation status and
Hippo-salvador association. PLoS Biol. 11:e10016202013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Genevet A, Wehr MC, Brain R, Thompson BJ
and Tapon N: Kibra is a regulator of the Salvador/Warts/Hippo
signaling network. Dev Cell. 18:300–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Meng Z, Moroishi T, Mottierpavie V,
Plouffe SW, Hansen CG, Hong AW, Park HW, Mo JS, Lu W, Lu S, et al:
MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2
in the Hippo pathway. Nat Commun. 6:83572015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yin F, Yu J, Zheng Y, Chen Q, Zhang N and
Pan D: Spatial organization of Hippo signaling at the plasma
membrane mediated by the tumor suppressor Merlin/NF2. Cell.
154:1342–1355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hirate Y, Hirahara S, Inoue K, Suzuki A,
Alarcon VB, Akimoto K, Hirai T, Hara T, Adachi M, Chida K, et al:
Polarity-dependent distribution of angiomotin localizes Hippo
signaling in preimplantation embryos. Curr Biol. 23:1181–1194.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huntoon CJ, Nye MD, Geng L, Peterson KL,
Flatten KS, Haluska P, Kaufmann SH and Karnitz LM: Heat shock
protein 90 inhibition depletes LATS1 and LATS2, two regulators of
the mammalian hippo tumor suppressor pathway. Cancer Res.
70:8642–8650. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Das Thakur M, Feng Y, Jagannathan R, Seppa
MJ, Skeath JB and Longmore GD: Ajuba LIM proteins are negative
regulators of the Hippo signaling pathway. Curr Biol. 20:657–662.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chan SW, Lim CJ, Huang C, Chong YF,
Gunaratne HJ, Hogue KA, Blackstock WP, Harvey KF and Hong W: WW
domain-mediated interaction with Wbp2 is important for the
oncogenic property of TAZ. Oncogene. 30:600–610. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu X, Yang N, Figel SA, Wilson KE,
Morrison CD, Gelman IH and Zhang J: PTPN14 interacts with and
negatively regulates the oncogenic function of YAP. Oncogene.
32:1266–1273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lian I, Kim J, Okazawa H, Zhao J, Zhao B,
Yu J, Chinnaiyan A, Israel MA, Goldstein LSB, Abujarour R, et al:
The role of YAP transcription coactivator in regulating stem cell
self-renewal and differentiation. Genes Dev. 24:1106–1118. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Camargo FD, Gokhale S, Johnnidis JB, Fu D,
Bell GW, Jaenisch R and Brummelkamp TR: YAP1 increases organ size
and expands undifferentiated progenitor cells. Curr Biol.
17:2054–2060. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xin M, Kim Y, Sutherland LB, Murakami M,
Qi X, Mcanally J, Porrello ER, Mahmoud AI, Tan W, Shelton JM, et
al: Hippo pathway effector Yap promotes cardiac regeneration. Proc
Natl Acad Sci USA. 110:13839–13844. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Schlegelmilch K, Mohseni M, Kirak O,
Pruszak J, Rodriguez JR, Zhou D, Kreger BT, Vasioukhin V, Avruch J,
Brummelkamp TR and Camargo FD: Yap1 acts downstream of α-catenin to
control epidermal proliferation. Cell. 144:782–795. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Heallen T, Zhang M, Wang J,
Bonilla-Claudio M, Klysik E, Johnson RL and Martin JF: Hippo
pathway inhibits Wnt signaling to restrain cardiomyocyte
proliferation and heart size. Science. 332:458–461. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang H, Pasolli HA and Fuchs E:
Yes-associated protein (YAP) transcriptional coactivator functions
in balancing growth and differentiation in skin. Proc Natl Acad Sci
USA. 108:2270–2275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
von Gise A, Lin Z, Schlegelmilch K, Honor
LB, Pan GM, Buck JN, Ma Q, Ishiwata T, Zhou B, Camargo FD and Pu
WT: YAP1, the nuclear target of Hippo signaling, stimulates heart
growth through cardiomyocyte proliferation but not hypertrophy.
Proc Natl Acad Sci USA. 109:2394–2399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Harvey KF, Pfleger CM and Hariharan IK:
The Drosophila Mst ortholog, hippo, restricts growth and
cell proliferation and promotes apoptosis. Cell. 114:457–467. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jia J, Zhang W, Wang B, Trinko R and Jiang
J: The Drosophila Ste20 family kinase dMST functions as a
tumor suppressor by restricting cell proliferation and promoting
apoptosis. Genes Dev. 17:2514–2519. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu
Q, Wang Y, Halder G, Finegold MJ, Lee JS and Johnson RL: Hippo
signaling is a potent in vivo growth and tumor suppressor pathway
in the mammalian liver. Proc Natl Acad Sci USA. 107:1437–1442.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xin M, Kim Y, Sutherland LB, Qi X,
Mcanally J, Schwartz RJ, Richardson JA, Basselduby R and Olson EN:
Regulation of insulin-like growth factor signaling by Yap governs
cardiomyocyte proliferation and embryonic heart size. Sci Signal.
4:ra702011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Johnson R and Halder G: The two faces of
Hippo: Targeting the Hippo pathway for regenerative medicine and
cancer treatment. Nat Rev Drug Discov. 13:63–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhou D, Conrad C, Xia F, Park JS, Payer B,
Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J and Bardeesy N: Mst1
and Mst2 maintain hepatocyte quiescence and suppress hepatocellular
carcinoma development through inactivation of the Yap1 oncogene.
Cancer Cell. 16:425–438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhu Q, Le ES, Jahchan N, Ji X, Xu A and
Luo K: SnoN antagonizes the Hippo kinase complex to promote TAZ
signaling during breast carcinogenesis. Dev Cell. 37:399–412. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jing Z, Wang G, Chu SJ, Zhu JS, Rui Z, Lu
WW, Xia LQ, Lu YM, Wei D and Sun Q: Loss of large tumor suppressor
1 promotes growth and metastasis of gastric cancer cells through
upregulation of the YAP signaling. Oncotarget. 7:16180–16193.
2016.PubMed/NCBI
|
|
57
|
Strazisar M, Mlakar V and Glavac D: LATS2
tumour specific mutations and down-regulation of the gene in
non-small cell carcinoma. Lung Cancer. 64:257–262. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ishizaki K, Fujimoto J, Kumimoto H,
Nishimoto Y, Shimada Y, Shinoda M and Yamamoto T: Frequent
polymorphic changes but rare tumor specific mutations of the LATS2
gene on 13q11-12 in esophageal squamous cell carcinoma. Int J
Oncol. 21:1053–1057. 2002.PubMed/NCBI
|
|
59
|
Bonilla X, Parmentier L, King B, Bezrukov
F, Kaya G, Zoete V, Seplyarskiy VB, Sharpe HJ, Mckee T, Letourneau
A, et al: Genomic analysis identifies new drivers and progression
pathways in skin basal cell carcinoma. Nat Genet. 48:398–406. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lee JH, Kavanagh JJ, Wildrick DM, Wharton
JT and Blick M: Frequent loss of heterozygosity on chromosomes 6q,
11, and 17 in human ovarian carcinomas. Cancer Res. 50:2724–2728.
1990.PubMed/NCBI
|
|
61
|
Theile M, Seitz S, Arnold W, Jandrig B,
Frege R, Schlag PM, Haensch W, Guski H, Winzer KJ, Barrett JC and
Scherneck S: A defined chromosome 6q fragment (at D6S310) harbors a
putative tumor suppressor gene for breast cancer. Oncogene.
13:677–685. 1996.PubMed/NCBI
|
|
62
|
Noviello C, Courjal F and Theillet C: Loss
of heterozygosity on the long arm of chromosome 6 in breast cancer:
Possibly four regions of deletion. Clin Cancer Res. 2:1601–1606.
1996.PubMed/NCBI
|
|
63
|
Chen KH, He J, Wang DL, Cao JJ, Li MC,
Zhao XM, Sheng X, Li WB and Liu WJ: Methylation-associated
inactivation of LATS1 and its effect on demethylation or
overexpression on YAP and cell biological function in human renal
cell carcinoma. Int J Oncol. 45:2511–2521. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Van Hateren NJ, Das RM, Hautbergue GM,
Borycki AG, Placzek M and Wilson SA: FatJ acts via the Hippo
mediator Yap1 to restrict the size of neural progenitor cell pools.
Development. 138:1893–1902. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Qi C, Zhu YT, Hu L and Zhu YJ:
Identification of Fat4 as a candidate tumor suppressor gene in
breast cancers. Int J Cancer. 124:793–798. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zang ZJ, Cutcutache I, Poon SL, Zhang SL,
Mcpherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, et al:
Exome sequencing of gastric adenocarcinoma identifies recurrent
somatic mutations in cell adhesion and chromatin remodeling genes.
Nat Genet. 44:570–574. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Mitamura T, Watari H, Wang L, Kanno H,
Miyazaki M, Kitagawa M, Hassan MK, Dong P, Kimura T, Tanino M and
Sakuragi N: MicroRNA 31 functions as an endometrial cancer oncogene
by suppressing Hippo tumor suppressor pathway. Mol Cancer.
13:972014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Tan G, Cao X, Dai Q, Zhang B, Huang J,
Xiong S, Zhang Y, Chen W, Yang J and Li H: A novel role for
microRNA-129-5p in inhibiting ovarian cancer cell proliferation and
survival via direct suppression of transcriptional co-activators
YAP and TAZ. Oncotarget. 6:8676–8686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Shen S, Guo X, Yan H, Lu Y, Ji X, Li L,
Liang T, Zhou D, Feng XH, Zhao JC, et al: A miR-130a-YAP positive
feedback loop promotes organ size and tumorigenesis. Cell Res.
25:997–1012. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhu G, Wang Y, Mijiti M, Wang Z, Wu PF and
Jiafu D: Upregulation of miR-130b enhances stem cell-like phenotype
in glioblastoma by inactivating the Hippo signaling pathway.
Biochem Biophys Res Commun. 465:194–199. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Riquelme I, Ili C, Roa JC and Brebi P:
Long non-coding RNAs in gastric cancer: Mechanisms and potential
applications. Oncotarget. 2016.doi: 10.18632/oncotarget.9396.
|
|
74
|
Gutschner T and Diederichs S: The
hallmarks of cancer: A long non-coding RNA point of view. RNA Biol.
9:703–719. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Chen Y, Wei G, Xia H, Yu H, Tang Q and Bi
F: Down regulation of lincRNA-p21 contributes to gastric cancer
development through Hippo-independent activation of YAP.
Oncotarget. 8:63813–63824. 2017.PubMed/NCBI
|
|
76
|
Qu S, Yue Z, Shang R, Xuan Z, Song W,
Kjems J and Li H: The emerging landscape of circular RNA in life
processes. RNA Biol. 14:992–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Qu S, Yang X, Li X, Wang J, Gao Y, Shang
R, Sun W, Dou K and Li H: Circular RNA: A new star of noncoding
RNAs. Cancer Lett. 365:141–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zhang J, Liu H, Hou L, Wang G, Zhang R,
Huang Y, Chen X and Zhu J: Circular RNA_LARP4 inhibits cell
proliferation and invasion of gastric cancer by sponging miR-424-5p
and regulating LATS1 expression. Mol Cancer. 16:1512017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
He M, Zhou Z, Shah AA, Yang H, Chen Q and
Wan Y: New insights into posttranslational modifications of Hippo
pathway in carcinogenesis and therapeutics. Cell Div. 11:42016.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Tomlinson V, Gudmundsdottir K, Luong P,
Leung KY, Knebel A and Basu S: JNK phosphorylates Yes-associated
protein (YAP) to regulate apoptosis. Cell Death Dis. 1:e292010.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Jang SW, Yang SJ, Srinivasan S and Ye K:
Akt phosphorylates MstI and prevents its proteolytic activation,
blocking FOXO3 phosphorylation and nuclear translocation. J Biol
Chem. 282:30836–30844. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Collak FK, Yagiz K, Luthringer DJ, Erkaya
B and Cinar B: Threonine-120 phosphorylation regulated by
phosphoinositide-3-kinase/Akt and mammalian target of rapamycin
pathway signaling limits the antitumor activity of mammalian
sterile 20-like kinase 1. J Biol Chem. 287:23698–23709. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Bi W, Xiao L, Jia Y, Wu J, Xie Q, Ren J,
Ji G and Yuan Z: c-Jun N-terminal kinase enhances MST1-mediated
pro-apoptotic signaling through phosphorylation at serine 82. J
Biol Chem. 285:6259–6264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Hata S, Hirayama J, Kajiho H, Nakagawa K,
Hata Y, Katada T, Furutaniseiki M and Nishina H: A novel
acetylation cycle of transcription co-activator Yes-associated
protein that is downstream of Hippo pathway is triggered in
response to SN2 alkylating agents. J Biol Chem. 287:22089–22098.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Mao B, Hu F, Cheng J, Wang P, Xu M, Yuan
F, Meng S, Wang Y, Yuan Z and Bi W: SIRT1 regulates YAP2-mediated
cell proliferation and chemoresistance in hepatocellular carcinoma.
Oncogene. 33:1468–1474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Oudhoff MJ, Freeman SA, Couzens AL,
Antignano F, Kuznetsova E, Min PH, Northrop JP, Lehnertz B,
Barsyte-Lovejoy D, Vedadi M, et al: Control of the hippo pathway by
Set7-dependent methylation of Yap. Dev Cell. 26:188–194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Kreppel LK, Blomberg MA and Hart GW:
Dynamic glycosylation of nuclear and cytosolic proteins. Cloning
and characterization of a unique O-GlcNAc transferase with multiple
tetratricopeptide repeats. J Biol Chem. 272:9308–9315. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Singh JP, Zhang K, Wu J and Yang X:
O-GlcNAc signaling in cancer metabolism and epigenetics. Cancer
Lett. 356:244–250. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Starska K, Forma E, Brzezińska-Błaszczyk
E, Lewy-Trenda I, Bryś M, Jóźwiak P and Krześlak A: Gene and
protein expression of O-GlcNAc-cycling enzymes in human laryngeal
cancer. Clin Exp Med. 15:455–468. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Itkonen HM, Minner S, Guldvik IJ, Sandmann
MJ, Tsourlakis MC, Berge V, Svindland A, Schlomm T and Mills IG:
O-GlcNAc transferase integrates metabolic pathways to regulate the
stability of c-MYC in human prostate cancer cells. Cancer Res.
73:5277–5287. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Zhang X, Qiao Y, Wu Q, Chen Y, Zou S, Liu
X, Zhu G, Zhao Y, Chen Y, Yu Y, et al: The essential role of YAP
O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis. Nat
Commun. 8:152802017. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Jennissen HP: Ubiquitin and the enigma of
intracellular protein degradation. Eur J Biochem. 231:1–30. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Hicke L: Protein regulation by
monoubiquitin. Nat Rev Mol Cell Biol. 2:195–201. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Berndsen CE and Wolberger C: New insights
into ubiquitin E3 ligase mechanism. Nat Struct Mol Biol.
21:301–307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Pickart CM: Mechanisms underlying
ubiquitination. Annu Rev Biochem. 70:503–533. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Thrower JS, Hoffman L, Rechsteiner M and
Pickart CM: Recognition of the polyubiquitin proteolytic signal.
EMBO J. 19:94–102. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wang X, Yang J, Han L, Zhao K, Wu Q, Bao
L, Li Z, Lv L and Li B: TRAF5-mediated Lys-63-linked
polyubiquitination plays an essential role in positive regulation
of RORγt in promoting IL-17A expression. J Biol Chem.
290:29086–29094. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Yang WL, Wu CY, Wu J and Lin HK:
Regulation of Akt signaling activation by ubiquitination. Cell
Cycle. 9:487–497. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Mukhopadhyay D and Riezman H:
Proteasome-independent functions of ubiquitin in endocytosis and
signaling. Science. 315:201–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Terrell J, Shih S, Dunn R and Hicke L: A
function for monoubiquitination in the internalization of a G
protein-coupled receptor. Mol Cell. 1:193–202. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Rome S, Meugnier E and Vidal H: The
ubiquitin-proteasome pathway is a new partner for the control of
insulin signaling. Curr Opin Clin Nutr Metab Care. 7:249–254. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Izzi L and Attisano L: Regulation of the
TGFbeta signalling pathway by ubiquitin-mediated degradation.
Oncogene. 23:2071–2078. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Lan Q, Gao Y, Li Y, Hong X and Xu P:
Progress in ubiquitin, ubiquitin chain and protein ubiquitination.
Sheng Wu Gong Cheng Xue Bao. 32:14–30. 2016.(In Chinese).
PubMed/NCBI
|
|
104
|
He M, Zhou Z, Shah AA, Zou H, Tao J, Chen
Q and Wan Y: The emerging role of deubiquitinating enzymes in
genomic integrity, diseases, and therapeutics. Cell Biosci.
6:622016. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Nijman SM, Luna-Vargas MP, Velds A,
Brummelkamp TR, Dirac AM, Sixma TK and Bernards R: A genomic and
functional inventory of deubiquitinating enzymes. Cell.
123:773–786. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Gao C, Huang W, Kanasaki K and Xu Y: The
role of ubiquitination and sumoylation in diabetic nephropathy.
Biomed Res Int 2014. 1606922014.
|
|
107
|
Chen Z and Lu W: Roles of ubiquitination
and SUMOylation on prostate cancer: Mechanisms and clinical
implications. Int J Mol Sci. 16:4560–4580. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Popovic D, Vucic D and Dikic I:
Ubiquitination in disease pathogenesis and treatment. Nat Med.
20:1242–1253. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Hong L, Huang HC and Jiang ZF:
Relationship between amyloid-beta and the ubiquitin-proteasome
system in Alzheimer's disease. Neurol Res. 36:276–282. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Debald M, Schildberg FA, Linke A,
Walgenbach K, Kuhn W, Hartmann G and Walgenbach-Brünagel G:
Specific expression of k63-linked ubiquitination of calmodulin-like
protein 5 in breast cancer of premenopausal patients. J Cancer Res
Clin Oncol. 139:2125–2132. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Zarrizi R, Menard JA, Belting M and
Massoumi R: Deubiquitination of gamma-tubulin by BAP1 prevents
chromosome instability in breast cancer cells. Cancer Res.
74:6499–6508. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Li X, Stevens PD, Yang H, Gulhati P, Wang
W, Evers BM and Gao T: The deubiquitination enzyme USP46 functions
as a tumor suppressor by controlling PHLPP-dependent attenuation of
Akt signaling in colon cancer. Oncogene. 32:471–478. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Bhattacharya S and Ghosh MK: Cell death
and deubiquitinases: Perspectives in cancer. Biomed Res Int 2014.
4351972014.
|
|
114
|
Burger AM and Seth AK: The
ubiquitin-mediated protein degradation pathway in cancer:
Therapeutic implications. Eur J Cancer. 40:2217–2229. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Hussain S, Zhang Y and Galardy PJ: DUBs
and cancer: The role of deubiquitinating enzymes as oncogenes,
non-oncogenes and tumor suppressors. Cell Cycle. 8:1688–1697. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Surget S, Khoury MP and Bourdon JC:
Uncovering the role of p53 splice variants in human malignancy: A
clinical perspective. Oncotargets Ther. 7:57–68. 2013.
|
|
117
|
Canner JA, Sobo M, Ball S, Hutzen B,
Deangelis S, Willis W, Studebaker AW, Ding K, Wang S, Yang D and
Lin J: MI-63: A novel small-molecule inhibitor targets MDM2 and
induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells
with wild-type p53. Br J Cancer. 101:774–781. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Meng X, Franklin DA, Dong J and Zhang Y:
MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res.
74:7161–7167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Brooks CL, Li M, Hu M, Shi Y and Gu W: The
p53-Mdm2-HAUSP complex is involved in p53 stabilization by HAUSP.
Oncogene. 26:7262–7266. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Hock AK, Vigneron AM, Carter S, Ludwig RL
and Vousden KH: Regulation of p53 stability and function by the
deubiquitinating enzyme USP42. EMBO J. 30:4921–4930. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Dolcet X, Llobet D, Pallares J and
Matias-Guiu X: NF-κB in development and progression of human
cancer. Virchows Arch. 446:475–482. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Häcker H and Karin M: Regulation and
function of IKK and IKK-related Kinases. Sci STKE 2006.
re132006.
|
|
123
|
Fuchs S: Activation of β-Trcp ubiquitin
ligases in cancers: Mechanisms and outcomes. Cancer Res.
67:2007.
|
|
124
|
Schweitzer K, Bozko PM, Dubiel W and
Naumann M: CSN controls NF-κB by deubiquitinylation of IκBα. EMBO
J. 26:1532–1541. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Harhaj EW and Dixit VM: Regulation of
NF-κB by deubiquitinases. Immunol Rev. 246:107–124. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Luise C, Capra M, Donzelli M, Mazzarol G,
Jodice MG, Nuciforo P, Viale G, Di Fiore PP and Confalonieri S: An
atlas of altered expression of deubiquitinating enzymes in human
cancer. PLoS One. 6:e158912011. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Priolo C, Tang D, Brahamandan M, Benassi
B, Sicinska E, Ogino S, Farsetti A, Porrello A, Finn S, Zimmermann
J, et al: The isopeptidase USP2a protects human prostate cancer
from apoptosis. Cancer Res. 66:8625–8632. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Metzig M, Nickles D, Falschlehner C,
Lehmann-Koch J, Straub BK, Roth W and Boutros M: An RNAi screen
identifies USP2 as a factor required for TNF-α-induced NF-κB
signaling. Int J Cancer. 129:607–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Hilman D and Gat U: The evolutionary
history of YAP and the hippo/YAP pathway. Mol Biol Evol.
28:2403–2417. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Avruch J, Zhou D, Fitamant J, Bardeesy N,
Mou F and Barrufet LR: Protein kinases of the Hippo pathway:
Regulation and substrates. Semin Cell Dev Biol. 23:770–784. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Yabuta N, Fujii T, Copeland NG, Gilbert
DJ, Jenkins NA, Nishiguchi H, Endo Y, Toji S, Tanaka H, Nishimune Y
and Nojima H: Structure, expression, and chromosome mapping of
LATS2, a mammalian homologue of the Drosophila tumor
suppressor gene lats/warts. Genomics. 63:263–270. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Nishiyama Y and Al E: A human homolog of
Drosophila warts tumor suppressor, h-warts, localized to
mitotic apparatus and specifically phosphorylated during mitosis.
FEBS Lett. 459:159–165. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Visser S and Yang X: LATS tumor
suppressor: A new governor of cellular homeostasis. Cell Cycle.
9:3892–3903. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Furth N and Aylon Y: The LATS1 and LATS2
tumor suppressors: Beyond the Hippo pathway. Cell Death Differ.
24:1488–1501. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Wang W, Li X, Huang J, Feng L, Dolinta KG
and Chen J: Defining the protein-protein interaction network of the
human hippo pathway. Mol Cell Proteomics. 13:119–131. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Lit LC, Scott S, Zhang H, Stebbing J,
Photiou A and Giamas G: LATS2 is a modulator of estrogen receptor
alpha. Anticancer Res. 33:53–63. 2013.PubMed/NCBI
|
|
137
|
Powzaniuk M, Mcelwee-Witmer S, Vogel RL,
Hayami T, Rutledge SJ, Chen F, Harada S, Schmidt A, Rodan GA,
Freedman LP and Bai C: The LATS2/KPM tumor suppressor is a negative
regulator of the androgen receptor. Mol Endocrinol. 18:2011–2023.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Britschgi A, Duss S, Kim S, Couto JP,
Brinkhaus H, Koren S, De Silva D, Mertz KD, Kaup D, Varga Z, et al:
The Hippo kinases LATS1 and 2 control human breast cell fate via
crosstalk with ERα. Nature. 541:541–545. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Moroishi T, Hayashi T, Pan WW, Fujita Y,
Holt MV, Qin J, Carson DA and Guan KL: The Hippo pathway kinases
LATS1/2 suppress cancer immunity. Cell. 167:1525–1539.e17. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Hershko A and Ciechanover A: The ubiquitin
system. Annu Rev Biochem. 67:425–79. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Boase NA and Kumar S: NEDD4: The founding
member of a family of ubiquitin-protein ligases. Gene. 557:113–122.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Bernassola F, Karin M, Ciechanover A,
Melino and Gerry: The HECT family of E3 ubiquitin ligases: Multiple
players in cancer development. Cancer Cell. 14:10–21. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Yang B and Kumar S: Nedd4 and Nedd4-2:
Closely related ubiquitin-protein ligases with distinct
physiological functions. Cell Death Differ. 17:68–77. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Salah Z, Melino G and Aqeilan RI: Negative
regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is
sufficient to promote tumorigenicity. Cancer Res. 71:2010–2020.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Salah Z, Itzhaki E and Aqeilan RI: The
ubiquitin E3 ligase ITCH enhances breast tumor progression by
inhibiting the Hippo tumor suppressor pathway. Oncotarget.
5:10886–10900. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Yeung B, Ho KC and Yang X: WWP1 E3 ligase
targets LATS1 for ubiquitin-mediated degradation in breast cancer
cells. PLoS One. 8:e610272013. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Bae SJ, Kim M, Kim SH, Kwon YE, Lee JH,
Kim J, Chung CH, Lee WJ and Seol JH: NEDD4 controls intestinal stem
cell homeostasis by regulating the Hippo signalling pathway. Nat
Commun. 6:63142015. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Wu S, Huang J, Dong J and Pan D: Hippo
encodes a Ste-20 family protein kinase that restricts cell
proliferation and promotes apoptosis in conjunction with salvador
and warts. Cell. 114:445–456. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Nakayama K, Qi J and Ronai Z: The
ubiquitin ligase Siah2 and the hypoxia response. Mol Cancer Res.
7:443–451. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Ma B, Chen Y, Chen L, Cheng H, Mu C, Li J,
Gao R, Zhou C, Cao L, Liu J, et al: Hypoxia regulates Hippo
signalling through the SIAH2 ubiquitin E3 ligase. Nat Cell Biol.
17:95–103. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Brown JM and Wilson WR: Exploiting tumour
hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Li W, Cooper J, Zhou L, Yang C,
Erdjument-Bromage H, Zagzag D, Snuderl M, Ladanyi M, Hanemann CO,
Zhou P, et al: Merlin/NF2 loss-driven tumorigenesis linked to
CRL4(DcAF1)-mediated inhibition of the hippo pathway kinases Latsl
and 2 in the nucleus. Cancer Cell. 26:48–60. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Lee J and Zhou P: DCAFs, the missing link
of the CUL4-DDB1 ubiquitin ligase. Mol Cell. 26:775–780. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Kim Y, Kim W, Song Y, Kim JR, Cho K, Moon
H, Ro SW, Seo E, Ryu YM, Myung SJ and Jho EH: Deubiquitinase YOD1
potentiates YAP/TAZ activities through enhancing ITCH stability.
Proc Natl Acad Sci USA. 114:4691–4696. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Kim Y and Jho EH: Deubiquitinase YOD1: The
potent activator of YAP in hepatomegaly and liver cancer. BMB Rep.
50:281–282. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Toloczko A, Guo F, Yuen HF, Wen Q, Wood
SA, Ong YS, Chan PY, Alli SA, Gunaratne J, Dunne MJ, et al:
Deubiquitinating enzyme USP9X suppresses tumor growth via LATS
kinase and core components of the hippo pathway. Cancer Res.
77:4921–4933. 2017.PubMed/NCBI
|
|
157
|
Thanh Nguyen H, Andrejeva D, Gupta R,
Choudhary C, Hong X, Eichhorn PJ, Loya AC and Cohen SM:
Deubiquitylating enzyme USP9× regulates hippo pathway activity by
controlling angiomotin protein turnover. Cell Discov. 2:160012016.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Okada T, Gondo Y, Goto J, Kanazawa I,
Hadano S and Ikeda JE: Unstable transmission of the RS447 human
megasatellite tandem repetitive sequence that contains the USP17
deubiquitinating enzyme gene. Hum Genet. 110:302–313. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Nguyen HT, Kugler JM and Cohen SM: DUB3
deubiquitylating enzymes regulate hippo pathway activity by
regulating the stability of ITCH, LATS and AMOT proteins. PLoS One.
12:e01695872017. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Salah Z, Alian A and Aqeilan RI: WW
domain-containing proteins: Retrospectives and the future. Front
Biosci (Landmark Ed). 17:331–348. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Kanai F, Marignani PA, Sarbassova D, Yagi
R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley LC
and Yaffe MB: TAZ: A novel transcriptional co-activator regulated
by interactions with 14-3-3 and PDZ domain proteins. EMBO J.
19:6778–6791. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Ye F and Zhang M: Structures and target
recognition modes of PDZ domains: Recurring themes and emerging
pictures. Biochem J. 455:1–14. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Remue E, Meerschaert K, Oka T, Boucherie
C, Vandekerckhove J, Sudol M and Gettemans J: TAZ interacts with
zonula occludens-1 and −2 proteins in a PDZ-1 dependent manner.
FEBS Lett. 584:4175–4180. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Jang EJ, Jeong H, Han KH, Kwon HM, Hong JH
and Hwang ES: TAZ suppresses NFAT5 activity through tyrosine
phosphorylation. Mol Cell Biol. 32:4925–4932. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Li Z, Zhao B, Wang P, Chen F, Dong Z, Yang
H, Guan KL and Xu Y: Structural insights into the YAP and TEAD
complex. Genes Dev. 24:235–240. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Howell M, Borchers C and Milgram SL:
Heterogeneous nuclear ribonuclear protein U associates with YAP and
regulates its co-activation of Bax transcription. J Biol Chem.
279:26300–26306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Sudol M: Yes-associated protein (YAP65) is
a proline-rich phosphoprotein that binds to the SH3 domain of the
Yes proto-oncogene product. Oncogene. 9:2145–2152. 1994.PubMed/NCBI
|
|
168
|
Cordenonsi M, Zanconato F, Azzolin L,
Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR,
Poletti A, et al: The Hippo transducer TAZ confers cancer stem
cell-related traits on breast cancer cells. Cell. 147:759–772.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Overholtzer M, Zhang J, Smolen GA, Muir B,
Li W, Sgroi DC, Deng CX, Brugge JS and Haber DA: Transforming
properties of YAP, a candidate oncogene on the chromosome 11q22
amplicon. Proc Natl Acad Sci USA. 103:12405–12410. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Kapoor A, Yao W, Ying H, Hua S, Liewen A,
Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, et al: Yap1 activation
enables bypass of oncogenic Kras addiction in pancreatic cancer.
Cell. 158:185–197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Attisano L and Wrana JL: Signal
integration in TGF-β, WNT, and Hippo pathways. F1000prime Rep.
5:172013. View
Article : Google Scholar : PubMed/NCBI
|
|
172
|
Cottini F, Hideshima T, Xu C, Sattler M,
Dori M, Agnelli L, ten Hacken E, Bertilaccio MT, Antonini E, Neri
A, et al: Rescue of Hippo co-activator yap1 triggers DNA
damage-induced apoptosis in hematological cancers. Nat Med.
20:599–606. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim
J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP
oncoprotein by the Hippo pathway is involved in cell contact
inhibition and tissue growth control. Genes Dev. 21:2747–2761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Zhao B, Li L, Tumaneng K, Wang CY and Guan
KL: A coordinated phosphorylation by Lats and CK1 regulates YAP
stability through SCFβ-TRCP. Genes Dev. 24:72–85. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Liu CY, Zha ZY, Zhou X, Zhang H, Huang W,
Zhao D, Li T, Chan SW, Lim CJ, Hong W, et al: The hippo tumor
pathway promotes TAZ degradation by phosphorylating a phosphodegron
and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem.
285:37159–37169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Deshaies RJ: SCF and Cullin/Ring H2-based
ubiquitin ligases. Annu Rev Cell Dev Biol. 15:435–467. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Bai C, Sen P, Hofmann K, Ma L, Goebl M,
Harper J and Elledge SJ: SKP1 connects cell cycle regulators to the
ubiquitin proteolysis machinery through a Novel motif, the F-Box.
Cell. 86:263–274. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Hart M, Concordet J, Lassot I, Albert I,
del los Santos R, Durand H, Perret C, Rubinfeld B, Margottin F,
Benarous R and Polakis P: The F-box protein β-TrCP associates with
phosphorylated beta-catenin and regulates its activity in the cell.
Curr Biol. 9:207–210. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Fuchs SY, Spiegelman VS and Kumar KG: The
many faces of beta-TrCP E3 ubiquitin ligases: Reflections in the
magic mirror of cancer. Oncogene. 23:2028–2036. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Tian Y, Kolb R, Hong JH, Carroll J, Li D,
You J, Bronson R, Yaffe MB, Zhou J and Benjamin T: TAZ promotes PC2
degradation through a SCFbeta-Trcp E3 ligase complex. Mol Cell
Biol. 27:6383–6395. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Yim H, Sung CK, You J, Tian Y and Benjamin
T: Nek1 and TAZ interact to maintain normal levels of polycystin 2.
J Am Soc Nephrol. 22:832–837. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Huang W, Lv X, Liu C, Zha Z, Zhang H,
Jiang Y, Xiong Y, Lei QY and Guan KL: The N-terminal phosphodegron
targets TAZ/WWTR1 protein for SCFβ-TrCP-dependent degradation in
response to phosphatidylinositol 3-Kinase inhibition. J Biol Chem.
287:26245–26253. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Zhao JJ and Roberts TM: PI3 kinases in
cancer: From oncogene artifact to leading cancer target. Sci STKE
2006. pe522006.
|
|
184
|
Wang Z, Inuzuka H, Zhong J, Wan L,
Fukushima H, Sarkar FH and Wei W: Tumor suppressor functions of
FBW7 in cancer development and progression. FEBS Lett.
586:1409–1418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Tu K, Yang W, Li C, Zheng X, Lu Z, Guo C,
Yao Y and Liu Q: Fbxw7 is an independent prognostic marker and
induces apoptosis and growth arrest by regulating YAP abundance in
hepatocellular carcinoma. Mol Cancer. 13:1102014. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Hong X, Nguyen HT, Chen Q, Zhang R, Hagman
Z, Voorhoeve PM and Cohen SM: Opposing activities of the Ras and
Hippo pathways converge on regulation of YAP protein turnover. EMBO
J. 33:2447–2457. 2015. View Article : Google Scholar
|
|
187
|
Linossi EM and Nicholson SE: The SOCS
box-adapting proteins for ubiquitination and proteasomal
degradation. IUBMB Life. 64:316–323. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Reddy BV and Irvine K: Regulation of Hippo
signaling by EGFR-MAPK signaling through Ajuba family proteins. Dev
Cell. 24:459–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Li L, Liu T, Li Y, Wu C, Luo K, Yin Y,
Chen Y, Nowsheen S, Wu J, Lou Z and Yuan J: The deubiquitinase
USP9X promotes tumor cell survival and confers chemoresistance
through YAP1 stabilization. Oncogene. 37:2422–2431. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Troyanovsky B, Levchenko T, Månsson G,
Matvijenko O and Holmgren L: Angiomotin: An angiostatin binding
protein that regulates endothelial cell migration and tube
formation. J Cell Biol. 152:1247–1254. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Bratt A, Wilson WJ, Troyanovsky B, Aase K,
Kessler R, Van Meir EG and Holmgren L: Angiomotin belongs to a
novel protein family with conserved coiled-coil and PDZ binding
domains. Gene. 298:69–77. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Ernkvist M, Aase K, Ukomadu C,
Wohlschlegel J, Blackman R, Veitonmäki N, Bratt A, Dutta A and
Holmgren L: p130-angiomotin associates to actin and controls
endothelial cell shape. FEBS J. 273:2000–2011. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Zetter BR: Hold that line. Angiomotin
regulates endothelial cell motility. J Cell Biol. 152:F35–F36.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q
and Guan KL: Angiomotin is a novel Hippo pathway component that
inhibits YAP oncoprotein. Genes Dev. 25:51–63. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Chan SW, Lim CJ, Chong YF, Pobbati AV,
Huang C and Hong W: Hippo pathway-independent restriction of TAZ
and YAP by angiomotin. J Biol Chem. 286:7018–7026. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Mana-Capelli S, Paramasivam M, Dutta S and
Mccollum D: Angiomotins link F-actin architecture to Hippo pathway
signaling. Mol Biol Cell. 25:1676–1685. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Varelas X, Samavarchi-Tehrani P, Narimatsu
M, Weiss A, Cockburn K, Larsen BG, Rossant J and Wrana JL: The
Crumbs complex couples cell density sensing to Hippo-dependent
control of the TGF-β-SMAD pathway. Dev Cell. 19:831–844. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Paramasivam M, Sarkeshik A, Yates JR III,
Fernandes MJ and Mccollum D: Angiomotin family proteins are novel
activators of the LATS2 kinase tumor suppressor. Mol Biol Cell.
22:3725–3733. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Chan SW, Lim CJ, Guo F, Tan I, Leung T and
Hong W: Actin-binding and cell proliferation activities of
angiomotin family members are regulated by Hippo pathway-mediated
phosphorylation. J Biol Chem. 288:37296–37307. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Yi C, Shen Z, Stemmer-Rachamimov A, Dawany
N, Troutman S, Showe LC, Liu Q, Shimono A, Sudol M, Holmgren L, et
al: The p130 isoform of angiomotin is required for Yap-mediated
hepatic epithelial cell proliferation and tumorigenesis. Sci
Signal. 6:ra772013. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Wang C, An J, Zhang P, Xu C, Gao K, Wu D,
Wang D, Yu H, Liu JO and Yu L: The Nedd4-like ubiquitin E3 ligases
target angiomotin/p130 to ubiquitin-dependent degradation. Biochem
J. 444:279–289. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Adler JJ, Heller BL, Bringman LR, Ranahan
WP, Cocklin RR, Goebl MG, Oh M, Lim HS, Ingham RJ and Wells CD:
Amot130 adapts atrophin-1 interacting protein 4 to inhibit
yes-associated protein signaling and cell growth. J Biol Chem.
288:15181–15193. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Skouloudaki K and Walz G: YAP1 recruits
c-Abl to protect angiomotin-like 1 from Nedd4-mediated degradation.
PLoS One. 7:e357352012. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Choi KS, Choi HJ, Lee JK, Im S, Zhang H,
Jeong Y, Park JA, Lee IK, Kim YM and Kwon YG: The endothelial E3
ligase HECW2 promotes endothelial cell junctions by increasing
AMOTL1 protein stability via K63-linked ubiquitination. Cell
Signal. 28:1642–1651. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Kim M, Kim M, Park SJ, Lee C and Lim DS:
Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition.
EMBO Rep. 17:64–78. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Mouchantaf R, Azakir BA, McPherson PS,
Millard SM, Wood SA and Angers A: The ubiquitin ligase itch is
auto-ubiquitylated in vivo and in vitro but is protected from
degradation by interacting with the deubiquitylating enzyme
FAM/USP9X. J Biol Chem. 281:38738–38747. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Chen HH, Mullett SJ and Stewart AF: Vgl-4,
a novel member of the vestigial-like family of transcription
cofactors, regulates alpha1-adrenergic activation of gene
expression in cardiac myocytes. J Biol Chem. 279:30800–30806. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Pobbati AV and Hong W: Emerging roles of
TEAD transcription factors and its coactivators in cancers. Cancer
Biol Ther. 14:390–398. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Pobbati A, Chan SW, Lee I, Song H and Hong
W: Structural and functional similarity between the Vgll1-TEAD and
the YAP-TEAD complexes. Structure. 20:1135–1140. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Hélias-Rodzewicz Z, Pérot G, Chibon F,
Ferreira C, Lagarde P, Terrier P, Coindre JM and Aurias A: YAP1 and
VGLL3, encoding two cofactors of TEAD transcription factors, are
amplified and overexpressed in a subset of soft tissue sarcomas.
Genes Chromosom Cancer. 49:1161–1171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Zhang Y, Shen H, Withers HG, Yang N,
Denson KE, Mussell AL, Truskinovsky A, Fan Q, Gelman IH, Frangou C
and Zhang J: VGLL4 selectively represses YAP-dependent gene
induction and tumorigenic phenotypes in breast cancer. Sci Rep.
7:61902017. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Jiang W, Yao F and He J, Lv B, Fang W, Zhu
W, He G, Chen J and He J: Downregulation of VGLL4 in the
progression of esophageal squamous cell carcinoma. Tumour Biol.
36:1289–1297. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Jin HS, Park HS, Shin JH, Kim DH, Jun SH,
Lee CJ and Lee TH: A novel inhibitor of apoptosis protein
(IAP)-interacting protein, Vestigial-like (Vgl)-4, counteracts
apoptosis-inhibitory function of IAPs by nuclear sequestration.
Biochem Biophys Res Commun. 412:454–459. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Zhang E, Shen B, Mu X, Qin Y, Zhang F, Liu
Y, Xiao J, Zhang P, Wang C, Tan M and Fan Y: Ubiquitin-specific
protease 11 (USP11) functions as a tumor suppressor through
deubiquitinating and stabilizing VGLL4 protein. Am J Cancer Res.
6:2901–2909. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Smith AL, Mitchell PJ, Shipley J,
Gusterson BA, Rogers MV and Crompton MR: Pez: A novel human cDNA
encoding protein tyrosine phosphatase- and ezrin-like domains.
Biochem Biophys Res Commun. 209:959–965. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Ogata M, Takada T, Mori Y, Oh-hora M,
Uchida Y, Kosugi A, Miyake K and Hamaoka T: Effects of
overexpression of PTP36, a putative protein tyrosine phosphatase,
on cell adhesion, cell growth, and cytoskeletons in HeLa cells. J
Biol Chem. 274:12905–12909. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Tonks NK: Protein tyrosine phosphatases:
From genes, to function, to disease. Nat Rev Mol Cell Biol.
7:833–846. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Wang W, Huang J, Wang X, Yuan J, Li X,
Feng L, Park JI and Chen J: PTPN14 is required for the
density-dependent control of YAP1. Genes Dev. 26:1959–1971. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Bosu DR and Kipreos ET: Cullin-RING
ubiquitin ligases: Global regulation and activation cycles. Cell
Div. 3:72008. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Jang LK, Lee ZH, Kim HH, Hill JM, Kim JD
and Kwon BS: A novel leucine-rich repeat protein (LRR-1): Potential
involvement in 4-1BB-mediated signal transduction. Mol Cells.
12:304–312. 2001.PubMed/NCBI
|
|
221
|
Walko G, Woodhouse S, Pisco AO, Rognoni E,
Liakath-Ali K, Lichtenberger BM, Mishra A, Telerman SB, Viswanathan
P, Logtenberg M, et al: A genome-wide screen identifies YAP/WBP2
interplay conferring growth advantage on human epidermal stem
cells. Nat Commun. 8:147442017. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Lim SK, Lu SY, Kang SA, Tan HJ, Li Z,
Adrian Wee ZN, Guan JS, Reddy Chichili VP, Sivaraman J, Putti T, et
al: Wnt signaling promotes breast cancer by blocking ITCH-mediated
degradation of YAP/TAZ transcriptional coactivator WBP2. Cancer
Res. 76:6278–6289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Avruch J, Xavier R, Bardeesy N, Zhang X,
Praskova M, Zhou D and Xia F: Rassf family of tumor suppressor
polypeptides. J Biol Chem. 284:11001–11005. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Volodko N, Gordon M, Salla M, Ghazaleh HA
and Baksh S: RASSF tumor suppressor gene family: Biological
functions and regulation. FEBS Lett. 588:2671–2684. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Iwasa H, Hossain S and Hata Y: Tumor
suppressor C-RASSF proteins. Cell Mol Life Sci. 75:1773–1787. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Agathanggelou A, Cooper WN and Latif F:
Role of the Ras-association domain family 1 tumor suppressor gene
in human cancers. Cancer Res. 65:3497–3508. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Richter AM, Pfeifer GP and Dammann RH: The
RASSF proteins in cancer; from epigenetic silencing to functional
characterization. Biochim Biophys Acta 1796. 114–128. 2009.
|
|
228
|
Oh HJ, Lee KK, Song SJ, Jin MS, Song MS,
Lee JH, Im CR, Lee JO, Yonehara S and Lim DS: Role of the tumor
suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res.
66:2562–2569. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Guo C, Zhang X and Pfeifer GP: The tumor
suppressor RASSF1A prevents dephosphorylation of the mammalian
STE20-like kinases MST1 and MST2. J Biol Chem. 286:6253–6261. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Matallanas D, Romano D, Yee K, Meissl K,
Kucerova L, Piazzolla D, Baccarini M, Vass JK, Kolch W and O'Neill
E: RASSF1A elicits apoptosis through an MST2 pathway directing
proapoptotic transcription by the p73 tumor suppressor protein. Mol
Cell. 27:962–975. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Bitra A, Sistla S, Mariam J, Malvi H and
Anand R: Rassf proteins as modulators of Mst1 kinase activity. Sci
Rep. 7:450202017. View Article : Google Scholar : PubMed/NCBI
|
|
232
|
Donninger H, Allen N, Henson A, Pogue J,
Williams A, Gordon L, Kassler S, Dunwell T, Latif F and Clark GJ:
Salvador protein is a tumor suppressor effector of RASSF1A with
hippo pathway-independent functions. J Biol Chem. 286:18483–18491.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Vlahov N, Scrace S, Soto MS, Grawenda AM,
Bradley L, Pankova D, Papaspyropoulos A, Yee KS, Buffa F, Goding
CR, et al: Alternate RASSF1 transcripts control SRC activity,
E-cadherin contacts, and YAP-mediated invasion. Curr Biol.
25:3019–3034. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Burbee D, Forgacs E, ZöchbauerMüller S,
Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S,
et al: Epigenetic inactivation of RASSF1A in lung and breast
cancers and malignant phenotype suppression. J Natl Cancer Inst.
93:691–699. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Pefani DE, Pankova D, Abraham A, Grawenda
A, Vlahov N, Scrace S and O'Neill E: TGF-β targets the Hippo
pathway scaffold RASSF1A to facilitate YAP/SMAD2 nuclear
translocation. Mol Cell. 63:156–166. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Suryaraja R, Anitha M, Anbarasu K, Kumari
G and Mahalingam S: The E3 ubiquitin ligase Itch regulates tumor
suppressor protein RASSF5/NORE1 stability in an
acetylation-dependent manner. Cell Death Dis. 4:e5652013.
View Article : Google Scholar : PubMed/NCBI
|
|
237
|
Kumari G, Singhal PK, Rao MR and
Mahalingam S: Nuclear transport of Ras-associated tumor suppressor
proteins: Different transport receptor binding specificities for
arginine-rich nuclear targeting signals. J Mol Biol. 367:1294–1311.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
238
|
Song MS, Song SJ, Kim SJ, Nakayama K,
Nakayama KI and Lim D: Skp2 regulates the antiproliferative
function of the tumor suppressor RASSF1A via ubiquitin-mediated
degradation at the G1-S transition. Oncogene. 27:3176–3185. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
239
|
Jiang L, Rong R, Sheikh MS and Huang Y:
Cullin-4A·DNA damage-binding protein 1 E3 ligase complex targets
tumor suppressor RASSF1A for degradation during mitosis. J Biol
Chem. 286:6971–6978. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Zhou X, Li TT, Feng X, Hsiang E, Xiong Y,
Guan KL and Lei QY: Targeted polyubiquitylation of RASSF1C by the
mule and SCFβ-TrCP ligases in response to DNA damage. Biochem J.
441:227–236. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
241
|
Mohseni M, Sun J, Lau A, Curtis S,
Goldsmith J, Fox VL, Wei C, Frazier M, Samson O, Wong KK, et al: A
genetic screen identifies an LKB1-MARK signalling axis controlling
the Hippo-YAP pathway. Nat Cell Biol. 16:108–117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
242
|
Nguyen HT, Kugler JM, Loya AC and Cohen
SM: USP21 regulates Hippo pathway activity by mediating MARK
protein turnover. Oncotarget. 8:64095–64105. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
243
|
Lignitto L, Arcella A, Sepe M, Rinaldi L,
Delle Donne R, Gallo A, Stefan E, Bachmann VA, Oliva MA, Tiziana
Storlazzi C, et al: Proteolysis of MOB1 by the ubiquitin ligase
praja2 attenuates Hippo signalling and supports glioblastoma
growth. Nat Commun. 4:18222013. View Article : Google Scholar : PubMed/NCBI
|
|
244
|
Ballinger CA, Connell P, Wu Y, Hu Z,
Thompson LJ, Yin LY and Patterson C: Identification of CHIP, a
novel tetratricopeptide repeat-containing protein that interacts
with heat shock proteins and negatively regulates chaperone
functions. Mol Cell Biol. 19:4535–4545. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
245
|
Ren A, Yan G, You B and Sun J:
Down-regulation of mammalian sterile 20-like kinase 1 by heat shock
protein 70 mediates cisplatin resistance in prostate cancer cells.
Cancer Res. 68:2266–2274. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
246
|
Xiao L, Chen D, Hu P, Wu J, Liu W, Zhao Y,
Cao M, Fang Y, Bi W, Zheng Z, et al: The c-Abl-MST1 signaling
pathway mediates oxidative stress-induced neuronal cell death. J
Neurosci. 31:9611–9619. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
247
|
Bao Y, Nakagawa K, Yang Z, Ikeda M,
Withanage K, Ishigami-Yuasa M, Okuno Y, Hata S, Nishina H and Hata
Y: A cell-based assay to screen stimulators of the Hippo pathway
reveals the inhibitory effect of dobutamine on the YAP-dependent
gene transcription. J Biochem. 150:199–208. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
248
|
Michels S and Schmidt-Erfurth U:
Photodynamic therapy with verteporfin: A new treatment in
ophthalmology. Semin Ophthalmol. 16:201–206. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
249
|
Liu-Chittenden Y, Huang B, Shim JS, Chen
Q, Lee SJ, Anders RA, Liu JO and Pan D: Genetic and pharmacological
disruption of the TEAD-YAP complex suppresses the oncogenic
activity of YAP. Genes Dev. 26:1300–1305. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
250
|
Huggett MT, Jermyn M, Gillams A, Illing R,
Mosse S, Novelli M, Kent E, Bown SG, Hasan T, Pogue BW and Pereira
SP: Phase I/II study of verteporfin photodynamic therapy in locally
advanced pancreatic cancer. Br J Cancer. 110:1698–1704. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
251
|
Kang W, Huang T, Zhou Y, Zhang J, Lung
RWM, Tong JHM, Chan AWH, Zhang B, Wong CC, Wu F, et al: miR-375 is
involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in
gastric carcinogenesis. Cell Death Dis. 9:922018. View Article : Google Scholar : PubMed/NCBI
|
|
252
|
Jiao S, Wang H, Shi Z, Dong A, Zhang W,
Song X, He F, Wang Y, Zhang Z, Wang W, et al: A peptide mimicking
VGLL4 function acts as a YAP antagonist therapy against gastric
cancer. Cancer Cell. 25:166–180. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
253
|
Yu FX, Zhao B, Panupinthu N, Jewell J,
Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, et al:
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor
signaling. Cell. 150:780–791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
254
|
Ponnusamy S, Selvam SP, Mehrotra S,
Kawamori T, Snider AJ, Obeid LM, Shao Y, Sabbadini R and Ogretmen
B: Communication between host organism and cancer cells is
transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate
signalling to regulate tumour metastasis. EMBO Mol Med. 4:761–775.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
255
|
Kelly MG, Mor G, Husband A, O'Malley DM,
Baker L, Azodi M, Schwartz PE and Rutherford TJ: Phase II
evaluation of phenoxodiol in combination with cisplatin or
paclitaxel in women with platinum/taxane-refractory/resistant
epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Int J Gynecol Cancer. 21:633–639. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
256
|
Laubach JP, Mitsiades CS, Roccaro AM,
Ghobrial IM, Anderson KC and Richardson PG: Clinical challenges
associated with bortezomib therapy in multiple myeloma and
Waldenstroms Macroglobulinemia. Leuk Lymphoma. 50:694–702. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
257
|
Wang W, Ren F, Wu Q, Jiang D, Li H, Peng
Z, Wang J and Shi H: MicroRNA-497 inhibition of ovarian cancer cell
migration and invasion through targeting of SMAD specific E3
ubiquitin protein ligase 1. Biochem Biophys Res Commun.
449:432–437. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
258
|
Zhu JY, Heidersbach A, Kathiriya IS, Garay
BI, Ivey KN, Srivastava D, Han Z and King IN: The E3 ubiquitin
ligase Nedd4/Nedd4L is directly regulated by microRNA 1.
Development. 144:866–875. 2017. View Article : Google Scholar : PubMed/NCBI
|
